Fundraising Foxブライトパス・バイオ㈱
Kawasaki, JP · 2 known investors
Find your way into ブライトパス・バイオ㈱
Sign up to see every warm intro you have to ブライトパス・バイオ㈱
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ブライトパス・バイオ㈱ team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
Founders & leadership
KN
Kenichi NagaiRepresentative Director & President
Investors · 2
Frequently asked questions
- What does ブライトパス・バイオ㈱ do?
- BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
- Who are ブライトパス・バイオ㈱'s investors?
- ブライトパス・バイオ㈱'s investors include DBJ Capital, Sumitomo Mitsui Trust nvestment Co. Ltd..
- Where is ブライトパス・バイオ㈱ headquartered?
- ブライトパス・バイオ㈱ is headquartered in Kawasaki, JP.